Clinical Trial Detail

NCT ID NCT03914625
Title Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute lymphoblastic leukemia

lymphoblastic lymphoma

Therapies

Cytarabine + Leucovorin + Methotrexate + Pegaspargase + Vincristine Sulfate

Blinatumomab + Dexamethasone + Methotrexate

Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate

Blinatumomab + Methotrexate

Mercaptopurine + Methotrexate + Vincristine Sulfate

Blinatumomab + Dexamethasone + Leucovorin + Methotrexate

Methotrexate + Pegaspargase + Vincristine Sulfate

Blinatumomab + Leucovorin + Methotrexate

Blinatumomab + Dexamethasone + Leucovorin

Mercaptopurine + Methotrexate + Prednisolone + Vincristine Sulfate

Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine Sulfate

Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Leucovorin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate

Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate

Cyclophosphamide + Cytarabine + Leucovorin + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate

Leucovorin + Methotrexate + Vincristine Sulfate

Methotrexate + Vincristine Sulfate

Dexamethasone + Mercaptopurine + Methotrexate + Vincristine Sulfate

Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate

Cytarabine + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate

Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate

Dexamethasone + Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate

Age Groups: child adult

No variant requirements are available.